Notably, treatment with these kinase inhibitors could be harnessed in future studies for the efficacious treatment of pancreatic cancer as monotherapy due to their deleterious impact on cell-survival-related signaling pathways such as apoptosis, cell cycle, ROS, and Bcl-2 and also upregulation of entities that inhibit metastasis, decrease chemoresistance, increase immunogenic cell death, and inhibit cancer gene transcription. This evidence concerns the gene BCL2 and pancreatic neoplasm.